使用中链甘油三糖的间歇性性禁食改善了与COQ8A相关的辅酶Q10缺乏症的性衰竭:一个案例报告
Wiebke Hahn1,2, Karla Erffmeier1,2, Maximilian Schulze3
1Department of Neurology, Philipps-University Marburg, Baldingerstraße, 35043 Marburg, Germany.
Molecular genetics and metabolism reports
|February 20, 2026
概括
基因性间歇性禁食改善了COQ8A相关的辅酶Q10缺乏症患者的动力衰竭. 这种饮食策略显示出作为线粒体动症的辅助疗法的前景,需要进一步的研究.
科学领域:
- 神经学 神经学
- 代谢障碍 代谢障碍 代谢障碍
- 线粒体疾病 线粒体疾病
背景情况:
- 在COQ8A的突变导致初级辅酶Q10的缺乏,导致各种神经症状,如小脑动和.
- 虽然辅酶Q10的补充是常见的,但对补充策略的证据,特别是对于非特征的证据是有限的.
研究的目的:
- 为了研究基因性间歇性禁食 (KIF) 的有效性,作为一种辅助治疗COQ8A相关的辅酶Q10缺乏症的患者的大脑动症的疗法.
主要方法:
- 一名46岁的女性患有遗传确认的COQ8A缺乏症和性衰竭/,接受了为期6个月的KIF协议 (16:8间歇性禁食与中链甘油三,随后仅间歇性禁食).
- 临床性动脉衰是使用动脉衰评估和评分尺度 (SARA) 进行评估的.
- 在干预之前和之后进行了脑部MRI,包括扩散成像.
主要成果:
- 观察到动力衰竭的显著改善,SARA分数从8.5降至6.0.
- 没有注意到肌肉发作的减少.
- 大脑MRI显示了大脑小脑微结构完整性改善的趋势.
结论:
- 基因性间歇性禁食可能作为对线粒体衰的有益辅助疗法.
- 这种饮食方法显示出改善COQ10缺乏症的动脉衰竭的潜力.
- 需要进行更大规模的研究来验证这些发现.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
223
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
223
Chronic Pancreatitis II: Collaborative Care
404
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
404
Metabolic States of the Body: Fasting and Starvation
3.0K
During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
3.0K
Animal Mitochondrial Genetics
9.4K
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
9.4K
Atherosclerosis III: Management
465
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
465
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
295
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
295


